Your Cart
Your cart is empty

Looks like you haven't added any test / checkup to your cart

Add Test / Checkup
Lab Test

MGMT by PCR (Temozolomide Resistance) - on Tissue

The MGMT by PCR (Temozolomide Resistance) - on Tissue test is a type of genetic test that is primarily used to predict how likely a patient's cancer, specifically glioblastoma, will respond to treatment with the chemotherapy drug temozolomide.


MGMT stands for O6-methylguanine-DNA methyltransferase. It's a gene that produces a protein that can repair certain types of damage to DNA. In some cancers, particularly glioblastoma, the MGMT gene is often "methylated" – meaning it's turned off. When the MGMT gene is turned off, the cancer cells are unable to repair the damage caused by temozolomide, making the drug more effective.

  • Profile Name: MGMT by PCR (Temozolomide Resistance) - on Tissue
  • Sample Type: Tissue
  • Preparations Required: No specific preparation is needed for this test, as the tissue sample will be collected by a healthcare professional during a surgical procedure or biopsy.
  • Report Time: 12 days

On the other hand, if the MGMT gene is "unmethylated" – meaning it's active – the cancer cells can repair the damage caused by temozolomide, making the drug less effective. This test, which is done on a sample of the cancer tissue, can determine the methylation status of the MGMT gene, providing insights into whether a patient is likely to respond to temozolomide treatment.

Home Sample Collection Process

1
Book your convenient slot
Book your convenient slot
2
Sample Collection by Phlebotomist
Sample Collection by Phlebotomist
3
Reporting of the sample at lab
Reporting of the sample at lab
4
Download Reports
Download Reports
Frequently Asked Questions

The test is performed on a sample of the tumor tissue, which is typically obtained during a surgical procedure or biopsy. The tissue is then sent to a laboratory, where technicians will use a technique called polymerase chain reaction (PCR) to amplify the DNA from the MGMT gene and then test it for methylation.

No special preparation is needed for this test. Your healthcare provider will instruct you on any necessary preparations for the biopsy or surgical procedure to obtain the tissue sample.

This test is typically recommended for individuals who have been diagnosed with glioblastoma and are being considered for treatment with temozolomide.

If the MGMT gene is methylated, it means that it's turned off. This suggests that the cancer cells may not be able to repair the damage caused by temozolomide, making the drug more effective.

If the MGMT gene is unmethylated, it means that it's active. This suggests that the cancer cells may be able to repair the damage caused by temozolomide, making the drug less effective.

Yes, the results of this test can significantly influence your treatment plan. If your MGMT gene is found to be methylated, your doctor may consider temozolomide as a suitable treatment option. If it's unmethylated, other treatments may be considered.

The turnaround time for this test can vary, but typically, results are available within 7 to 10 days.

You should continue your discussions with your oncologist, who is specialized in cancer care and can guide your treatment based on the results of this test.

No, the methylation status of the MGMT gene in your tumor cells is not something that you can change through lifestyle modifications.

The risks associated with this test are primarily related to the biopsy or surgical procedure used to obtain the tissue sample. Your healthcare provider will discuss these with you before the procedure.

The test only provides information about the MGMT gene methylation status in the specific tissue sample tested. This may not reflect the status throughout the entire tumor due to tumor heterogeneity. It is also only one factor among many that can influence how a cancer responds to treatment.

The test is generally accurate in determining the methylation status of the MGMT gene in the sample tested. However, it cannot guarantee whether the cancer will respond to temozolomide, as other factors can also affect drug response.

Other tests, such as imaging studies and other molecular tests, might be done in conjunction with this test to provide a more comprehensive view of your cancer and how it may respond to treatment.

The methylation status of the MGMT gene in a tumor can potentially change over time or in response to treatment. However, more research is needed to understand this fully.

No, the methylation status of the MGMT gene is not something that can be influenced by your actions or lifestyle. It is a characteristic of your tumor.

In summary, the MGMT by PCR (Temozolomide Resistance) - on Tissue test provides important information that can influence the treatment plan for individuals with glioblastoma. By understanding the status of the MGMT gene in the tumor, doctors can make more informed decisions about whether to use temozolomide as part of the treatment plan.

MGMT by PCR (Temozolomide Resistance) - on Tissue
₹ 16300 Book Test
Schedule Test in Your Available Time
Locations Near You in Hyderabad
  • 4KM from Madhapur
  • 3KM from Banjara Hills
  • 1.9KM from Yusufguda
  • 3KM from Madhura Nagar
  • 5KM from Shaikpet